CervoMed Expands Team With Strategic Hire To Advance Neflamapimod Development And Market Readiness

CervoMed Inc., a clinical-stage company focused on developing therapies for age-related neurological disorders, has announced a key addition to its senior leadership team. The company has appointed Marco Verwijs, PhD, as Executive Vice President of Technical Operations, effective June 2025. In his new role, Dr. Verwijs will lead the Chemistry, Manufacturing, and Controls (CMC) division, playing a critical role in advancing the development of CervoMed’s lead candidate, neflamapimod, through Phase 3 clinical trials and preparation for commercial-scale manufacturing.

John Alam, MD, Chief Executive Officer of CervoMed, stated, “We are pleased to welcome Dr. Verwijs to our leadership team as we embark on the next steps in the neflamapimod development pathway. We believe that Marco will serve a pivotal function in assuring product quality as we advance neflamapimod into Phase 3 in dementia with Lewy Bodies (DLB) in mid-2026 and prepare for future regulatory filings and potential commercial launch. We look forward to leveraging his impressive skill set at this critical juncture for the Company as we prepare to initiate the Phase 3 pivotal trial in DLB.”

Dr. Verwijs brings extensive experience in drug development, spanning from early preclinical stages to new drug application (NDA) submission and commercial launch. Prior to joining CervoMed, he served as Chief Technical Officer at Adipo Therapeutics. Throughout his career, he has specialized in drug product and process development, scale-up, and validation. His expertise covers all key aspects of CMC operations, including supply chain management and quality assurance. He has also held senior leadership positions at several Boston-based biotech companies, including Aerovate, Epizyme, Flexion, and Vertex.